Clinical trials: Neoplasms, Metastatic
Lung Cancer
Feasibility of re Biopsies at Progression
Feasibility of new biological and histological samples at progression in patients with advanced or metastatic Non Small Cell Lung Cancer (NSCLC). A recent paper from Professor Sequist and coll.
- Trial name
- GFPC-REBIOP (NCT02086071)
- Testing
- re biopsy
- Where
- 9 sites in France
- Volunteers
- 100 people
- Sponsor
- Groupe Francais De Pneumo-Cancerologie
Head and Neck Squamous Cell Carcinoma, Oncolytic Virus
H101 Plus TACE for r/m HNSCC
This study evaluates H101 combined with transarterial chemoembolization (TACE) to enhance local tumor killing and immune activation while minimizing toxicity in r/m HNSCC patients.
- Conditions
- Head and Neck Squamous Cell Carcinoma, Oncolytic Virus, TACE
- Trial name
- NCT07398664
- Testing
- H101, TACE
- Where
- China
- Volunteers
- 20 people
- Sponsor
- West China Hospital
Cutaneous Melanoma
Neoadjuvant Atezolizumab in Cutaneous Melanoma
The purpose of this research study is to see whether using atezolizumab before surgery is safe and does not cause side effects that delay surgery in participants with cutaneous melanoma that has not spread to other areas of the…
- Trial name
- NCT04020809
- Testing
- Atezolizumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- The Methodist Hospital Research Institute
Essential Thrombocythemia, Myelofibrosis
Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms
This phase I/II trial studies the best dose of ruxolitinib when given together with CPX-351 and to see how well they work in treating patients with accelerated phase or blast phase myeloproliferative neoplasm.
- Conditions
- Essential Thrombocythemia, Myelofibrosis, Myeloproliferative Neoplasm, Polycythemia Vera
- Trial name
- NCT03878199
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Liposome-encapsulated Daunorubicin-Cytarabine, Ruxolitinib
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Metastatic Breast Cancer
Nivolumab and Eribulin in HER2 Negative Metastatic Breast Cancer
Cancer therapeutics such as chemotherapy may modulate tumor/immune-system interactions in favor of the immune system. Chemotherapy can result in tumor cell death with a resultant increase in tumor antigen delivery to…
- Trial name
- KORNELIA (NCT04061863)
- Testing
- Nivolumab
- Where
- South Korea
- Volunteers
- 90 people
- Sponsor
- Seoul National University Hospital
OligoProgressive Metastatic Disease, Non-Small Cell Lung Cancer
Standard-of-care Systemic Therapy With or Without Local Therapy in Patients With Oligoprogressive Non-Small Cell Lung Cancer(NSCLC）
This is a randomized, controlled, phase II/III clinical study to evaluate the efficacy and safety of stand-of-care systemic therapy with local therapy versus stand-of-care systemic therapy in patients with oligoprogressive…
- Trial name
- NCT07076693
- Testing
- Radiotherapy or Surgery, Standard Medical Therapy
- Where
- China
- Volunteers
- 97 people
- Sponsor
- Shanghai Chest Hospital
Resistant Breast Cancer, Non-metastatic Invasive Breast Cancer
Capecitabine and Radiotherapy in the Adjuvant Treatment of Resistant Breast Cancer
This is a single-arm, prospective, non-randomized, feasibility study evaluating concurrent capecitabine-radiotherapy in participants with Resistant Breast Cancer.
- Trial name
- NCT03958721
- Testing
- Capecitabine, Radiotherapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- A Bapsi Chakravarthy, MD
Breast Cancer
Abiraterone Acetate in Molecular Apocrine Breast Cancer
The purpose of this study is to estimate antitumour activity of abiraterone acetate in Patients with a Molecular Apocrine HER2-negative locally advanced or metastatic Breast Cancer.
- Trial name
- AMA (NCT01842321)
- Testing
- Abiraterone Acetate
- Where
- 36 sites in France
- Volunteers
- 34 people
- Sponsor
- UNICANCER
Metastatic Castration-resistant Prostate Cancer, mCRPC
Clinical Evaluation of 177Lu-DansyI-PSMA (LNC1011) in Patients With Metastatic Castration-Resistant Prostate Cancer
Ten to 20% of patients with prostate cancer (PC) experience progression in their disease, even after undergoing pharmaceutical or surgical castration, leading to metastatic CRPC (mCRPC).
- Trial name
- NCT06377683
- Testing
- 177Lu-Dansyl-PSMA radioligand therapy
- Where
- China
- Volunteers
- 8 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Colorectal Neoplasms, Liver Neoplasms
Neo-adjuvant Therapy and the Effect on Synchronous Metastatic Growth
Study Hypothesis As well as in animal models as in patients with colorectal cancer resection of the primary tumor resulted in increase in vascular density, metabolism and secondary tumor growth of the distant metastases.
- Trial name
- NCT00659022
- Testing
- immediate surgery (resection of primary colorectal tumor), neo-adjuvant treatment with bevacizumab, neoadjuvant treatment with capecitabine and oxaliplatin
- Where
- 2 sites in Netherlands
- Volunteers
- 60 people
- Sponsor
- Radboud University Medical Center
Squamous Cell Carcinoma of the Head and Neck
Randomised Phase II, Cetuximab in Combination With 5FU and Cisplatin or Carboplatin Versus Cetuximab in Combination With Paclitaxel and Carboplatin for Treatment of Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck
Primary To investigate in patients with relapsed or metastatic squamous cell carcinoma of the head and neck whether progression free survival (PFS) in the arm with cetuximab, paclitaxel and carboplatin based chemotherapy is not…
- Trial name
- CETMET (NCT01830556)
- Testing
- Cetuximab
- Where
- 5 sites in Denmark, Sweden
- Volunteers
- 120 people
- Sponsor
- Karolinska University Hospital
Colorectal Cancer
Eniluracil and Surgery in Treating Patients With Primary or Metastatic Colorectal Cancer
RATIONALE: Eniluracil may increase the effectiveness of chemotherapy by blocking tumor enzymes that break down chemotherapy drugs.
- Trial name
- NCT00004195
- Testing
- eniluracil, conventional colon surgery
- Volunteers
- 28 people
- Sponsor
- University of Alabama at Birmingham
Breast Cancer, Neoadjuvant Therapy
Minimal Invasive Axillary Staging and Treatment After Neoadjuvant Systemic Therapy in Node Positive Breast Cancer
Today, the majority of clinically node positive (cN+) breast cancer patients is treated with neoadjuvant systemic therapy (NST). Axillary staging and treatment after NST in cN+ patients are areas of controversy.
- Conditions
- Breast Cancer, Neoadjuvant Therapy, Lymph Node Metastases
- Trial name
- MINIMAX (NCT04486495)
- Where
- 35 sites in Netherlands
- Volunteers
- 549 people
- Sponsor
- Maastricht University Medical Center
Cancer, Overall Survival
Study of the Safety, Tolerability and Efficacy of Metabolic Combination Treatments on Cancer
The purpose of this study is to determine the effectiveness of a regimen of selected metabolic treatments for patients with cancer in a real world setting and to conduct exploratory analysis on the relationship between the degree…
- Trial name
- METRICS (NCT02201381)
- Testing
- Metabolic treatment
- Where
- United Kingdom
- Sponsor
- Health Clinics Limited
Breast Cancer, Colorectal Cancer
Study of Circulating Cancer Cells in Patients With Metastatic Breast, Ovarian, Colon, or Pancreatic Cancer
RATIONALE: Counting the number of circulating cancer cells in samples of blood from patients with metastatic cancer may help doctors find out how much the cancer has spread.
- Conditions
- Breast Cancer, Colorectal Cancer, Ovarian Cancer, Pancreatic Cancer
- Trial name
- NCT00898781
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Mayo Clinic
Colorectal Cancer
Combination Chemotherapy With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. SU5416 may stop the growth of tumor cells by stopping blood flow to the tumor.
- Trial name
- NCT00021281
- Testing
- FOLFIRI regimen, fluorouracil, irinotecan hydrochloride
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Colorectal Cancer Metastatic, Early Response Evaluation
PET Evaluation of Response After 1 Course of Chemotherapy as Predictor of Treatment Outcome.
Study hypothesis : early decrease in fdg-pet measured SUV max after 1 cycle of chemotherapy can accurately predict response of chemotherapy as assessed by conventional radiology after 3 cycles of chemotherapy.
- Conditions
- Colorectal Cancer Metastatic, Early Response Evaluation, Fdg-PET
- Trial name
- earlyPETmCRC (NCT00741481)
- Testing
- FDG-PET imaging
- Where
- Belgium
- Volunteers
- 40 people
- Sponsor
- Jules Bordet Institute
Malignant Testicular Germ Cell Tumor
MAGESTIC Trial: MiRNA in Detecting Active Germ Cell Tumors in Early Suspected and MetastaTIC Disease Trial
This study evaluates the accuracy of blood-based biomarker testing to predict the presence of active testicular cancer.
- Trial name
- NCT06060873
- Testing
- Clinical Stage I Disease, Clinical Stage I with relapse, CSII Disease
- Where
- 7 sites in United States, Canada
- Volunteers
- 418 people
- Sponsor
- University of Southern California
Kidney Cancer, Melanoma (Skin)
Cryoablation or External-Beam Radiation Therapy in Treating Patients With Painful Bone Metastases
RATIONALE: Cryoablation kills cancer cells by freezing them. Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells.
- Conditions
- Kidney Cancer, Melanoma (Skin), Metastatic Cancer, Pain
- Trial name
- NCT00540969
- Testing
- cryosurgery, radiation therapy
- Where
- 7 sites in United States
- Volunteers
- 3 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Neuroendocrine Tumors, Metastases, Neoplasm
High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors
The goal of this clinical research study is to learn if I-131 Metaiodobenzylguanidine (MIBG) can shrink or slow the growth of the tumor(s) in patients with metastatic neuroendocrine tumors.
- Trial name
- NCT00037869
- Testing
- I-131 Metaiodobenzylguanidine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.